Scholars@Duke
Xanne Hoyt-Miggelbrink

Xanne Hoyt-Miggelbrink

Postdoctoral Associate
Integrative Immunobiology

Selected Publications

Peptide Vaccines for Pediatric High-Grade Glioma and Diffuse Midline Glioma: Current Progress and Future Perspectives.

Journal Article Vaccines (Basel) · November 30, 2025 High-grade gliomas (HGGs) and diffuse midline gliomas (DMGs) in pediatric patients carry a poor prognosis, necessitating the rapid development of novel therapies. Peptide vaccines represent a safe, repeatable, and rational immunotherapeutic modality aimed ... Full text Link to item Cite

Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity.

Journal Article Clin Cancer Res · November 21, 2025 PURPOSE: Exhaustion represents a collection of programmed T cell differentiation states and an important mode of T cell dysfunction. T cell progression from progenitor to terminal exhaustion is associated with upregulation of the transcription factor TOX. ... Full text Link to item Cite

CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis.

Journal Article Nat Cancer · September 2023 The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8+ T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex (MHC) class I (MHC-I) molecules. Likewise, ... Full text Link to item Cite

Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma.

Journal Article Nat Commun · October 29, 2022 Glioblastoma (GBM) is notorious for its immunosuppressive tumor microenvironment (TME) and is refractory to immune checkpoint blockade (ICB). Here, we identify calmodulin-dependent kinase kinase 2 (CaMKK2) as a driver of ICB resistance. CaMKK2 is highly ex ... Full text Link to item Cite